Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects

Trial Profile

Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2013

At a glance

  • Drugs GLPG 1205 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions
  • Sponsors Galapagos NV
  • Most Recent Events

    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Jul 2013 New trial record
    • 02 Jul 2013 Top-line results are expected to be reported at the end of 2013, according to a Galapagos NV media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top